{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:12:21Z","timestamp":1784297541619,"version":"3.55.0"},"reference-count":97,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sunway University","award":["GRTIN-RF-01-2021"],"award-info":[{"award-number":["GRTIN-RF-01-2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>SARS-CoV-2 has caused the COVID-19 pandemic, with over 673 million infections and 6.85 million deaths globally. Novel mRNA and viral-vectored vaccines were developed and licensed for global immunizations under emergency approval. They have demonstrated good safety and high protective efficacy against the SARS-CoV-2 Wuhan strain. However, the emergence of highly infectious and transmissible variants of concern (VOCs) such as Omicron was associated with considerable reductions in the protective efficacy of the current vaccines. The development of next-generation vaccines that could confer broad protection against both the SARS-CoV-2 Wuhan strain and VOCs is urgently needed. A bivalent mRNA vaccine encoding the Spike proteins of both the SARS-CoV-2 Wuhan strain and the Omicron variant has been constructed and approved by the US FDA. However, mRNA vaccines are associated with instability and require an extremely low temperature (\u221280 \u00b0C) for storage and transportation. They also require complex synthesis and multiple chromatographic purifications. Peptide-based next-generation vaccines could be developed by relying on in silico predictions to identify peptides specifying highly conserved B, CD4+ and CD8+ T cell epitopes to elicit broad and long-lasting immune protection. These epitopes were validated in animal models and in early phase clinical trials to demonstrate immunogenicity and safety. Next-generation peptide vaccine formulations could be developed to incorporate only naked peptides, but they are costly to synthesize and production would generate extensive chemical waste. Continual production of recombinant peptides specifying immunogenic B and T cell epitopes could be achieved in hosts such as E. coli or yeast. However, recombinant protein\/peptide vaccines require purification before administration. The DNA vaccine might serve as the most effective next-generation vaccine for low-income countries, since it does not require an extremely low temperature for storage or need extensive chromatographic purification. The construction of recombinant plasmids carrying genes specifying highly conserved B and T cell epitopes meant that vaccine candidates representing highly conserved antigenic regions could be rapidly developed. Poor immunogenicity of DNA vaccines could be overcome by the incorporation of chemical or molecular adjuvants and the development of nanoparticles for effective delivery.<\/jats:p>","DOI":"10.3390\/v15030624","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T04:05:40Z","timestamp":1677470740000},"page":"624","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern"],"prefix":"10.3390","volume":"15","author":[{"given":"Abdul Aziz","family":"Al-Fattah Yahaya","sequence":"first","affiliation":[{"name":"Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Bandar Sunway, Petaling Jaya 47500, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwal","family":"Khalid","sequence":"additional","affiliation":[{"name":"Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Bandar Sunway, Petaling Jaya 47500, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Xuan","family":"Lim","sequence":"additional","affiliation":[{"name":"Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Bandar Sunway, Petaling Jaya 47500, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8475-6291","authenticated-orcid":false,"given":"Chit Laa","family":"Poh","sequence":"additional","affiliation":[{"name":"Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Bandar Sunway, Petaling Jaya 47500, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ljungberg, K., and Isaguliants, M. (2020). DNA vaccine development at pre- and post-operation warp speed. Vaccines, 8.","DOI":"10.3390\/vaccines8040737"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e1017","DOI":"10.1016\/S2214-109X(21)00140-6","article-title":"Operation warp speed: Implications for global vaccine security","volume":"9","author":"Kim","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kyriakidis, N.C., L\u00f3pez-Cort\u00e9s, A., Gonz\u00e1lez, E.V., Grimaldos, A.B., and Prado, E.O. (2021). SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates. NPJ Vaccines, 6.","DOI":"10.1038\/s41541-021-00292-w"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41564-021-00932-w","article-title":"SARS-CoV-2 variants of interest and concern naming scheme conducive for global discourse","volume":"6","author":"Konings","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Noh, J.Y., Jeong, H.W., and Shin, E.C. (2021). SARS-CoV-2 mutations, vaccines, and immunity: Implication of variants of concern. Signal. Transduct. Target., 6.","DOI":"10.1038\/s41392-021-00623-2"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Meng, B., Kemp, S.A., Papa, G., Datir, R., Ferreira, I., Marelli, S., Harvey, W.T., Lytras, S., Mohamed, A., and Gallo, G. (2021). Recurrent emergence of SARS-CoV-2 spike deletion H69\/V70 and its role in the Alpha variant B.1.1.7. Cell Rep., 35.","DOI":"10.1016\/j.celrep.2021.109292"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s41564-021-00954-4","article-title":"SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution","volume":"6","author":"Zahradnik","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","article-title":"Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies","volume":"27","author":"Planas","year":"2021","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cell.2020.09.032","article-title":"Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant","volume":"183","author":"Yurkovetskiy","year":"2020","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Flores-Vega, V.R., Monroy-Molina, J.V., Jimenez-Hernandez, L.E., Torres, A.G., Santos-Preciado, J.I., and Rosales-Reyes, R. (2022). SARS-CoV-2: Evolution and emergence of new viral variants. Viruses, 14.","DOI":"10.3390\/v14040653"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Dol, J., Boulos, L., Somerville, M., Saxinger, L., Doroshenko, A., Hastings, S., Reynolds, B., Gallant, A., Shin, H.D., and Wong, H. (2022). Health system impacts of SARS-CoV\u2009-\u20092 variants of concern: A rapid review. BMC Health Serv. Res., 22.","DOI":"10.1186\/s12913-022-07847-0"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jiph.2021.12.011","article-title":"Isolation and characterization of SARS-CoV-2 Beta variant from UAE travelers","volume":"15","author":"Yadav","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ramesh, S., Govindarajulu, M., Parise, R.S., Neel, L., Shankar, T., Patel, S., Lowery, P., Smith, F., Dhanasekaran, M., and Moore, T. (2021). Emerging SARS-CoV-2 variants: A review of its mutations, its implications and vaccine efficacy. Vaccines, 9.","DOI":"10.3390\/vaccines9101195"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Tian, D., Sun, Y., Zhou, J., and Ye, Q. (2021). The global epidemic of the SARS-CoV-2 Delta variant, key apike mutations and immune escape. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.751778"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ou, J., Lan, W., Wu, X., Zhao, T., Duan, B., Yang, P., Ren, Y., Quan, L., Zhao, W., and Seto, D. (2022). Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events. Signal. Transduct. Target. Ther., 7.","DOI":"10.1038\/s41392-022-00992-2"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hoffmann, M., Zhang, L., and Pohlmann, S. (2022). Omicron: Master of immune evasion maintains robust ACE2 binding. Signal. Transduct. Target. Ther., 7.","DOI":"10.1038\/s41392-022-00965-5"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zhang, L., Jackson, C.B., Mou, H., Ojha, A., Peng, H., Quinlan, B.D., Rangarajan, E.S., Pan, A., Vanderheiden, A., and Suthar, M.S. (2020). SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun., 11.","DOI":"10.1038\/s41467-020-19808-4"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1002\/jmv.27062","article-title":"Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K","volume":"93","author":"Mercatelli","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Tchesnokova, V., Kulasekara, H., Larson, L., Bowers, V., Rechkina, E., Kisiela, D., Sledneva, Y., Choudhury, D., Maslova, I., and Deng, K. (2021). Acquisition of the L452R mutation in the ACE2-binding interface of spike protein triggers recent massive expansion of SARS-CoV-2 variants. J. Clin. Microbiol., 59.","DOI":"10.1128\/JCM.00921-21"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","article-title":"Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Shah, M., and Woo, H.G. (2021). Omicron: A heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.830527"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.cell.2022.03.038","article-title":"mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron","volume":"185","author":"Gagne","year":"2022","journal-title":"Cell"},{"key":"ref_29","unstructured":"(2023, January 19). Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. 31 August 2022, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use."},{"key":"ref_30","unstructured":"(2023, January 19). Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4\/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older. 31 August 2022. Available online: https:\/\/www.globenewswire.com\/en\/news-release\/2022\/08\/31\/2507787\/0\/en\/Pfizer-and-BioNTech-Granted-FDA-Emergency-Use-Authorization-of-Omicron-BA-4-BA-5-Adapted-Bivalent-COVID-19-Vaccine-Booster-for-Ages-12-Years-and-Older.html."},{"key":"ref_31","unstructured":"(2023, January 19). Pfizer and BioNTech Announce Positive Early Data from Clinical Trial of Omicron BA.4\/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older. 13 October 2022. Available online: https:\/\/www.globenewswire.com\/en\/news-release\/2022\/10\/13\/2533650\/0\/en\/Pfizer-and-BioNTech-Announce-Positive-Early-Data-From-Clinical-Trial-of-Omicron-BA-4-BA-5-Adapted-Bivalent-Booster-in-Individuals-18-Years-and-Older.html."},{"key":"ref_32","unstructured":"(2023, January 19). Coronavirus (COVID-19) Update: FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age. 8 December 2022, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-updated-bivalent-covid-19-vaccines-children-down-6-months."},{"key":"ref_33","unstructured":"(2023, January 19). European Medicines Agency Accepts Moderna\u2019s Conditional Marketing Authorization Filing for Its Omicron BA.4\/BA.5 Targeting Bivalent COVID-19 Vaccine. 28 September 2022. Available online: https:\/\/investors.modernatx.com\/news\/news-details\/2022\/European-Medicines-Agency-Accepts-Modernas-Conditional-Marketing-Authorization-Filing-for-its-Omicron-BA.4BA.5-Targeting-Bivalent-COVID-19-Vaccine\/default.aspx."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41591-022-02092-8","article-title":"Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice","volume":"29","author":"Scheaffer","year":"2022","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Hajnik, R.L., Plante, J.A., Liang, Y., Alameh, M.-G., Tang, J., Bonam, S.R., Zhong, C., Adam, A., Scharton, D., and Rafael, G.H. (2022). Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. Sci. Transl. Med., 14.","DOI":"10.1126\/scitranslmed.abq1945"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Tan, W., Lou, Z., Zhao, Y., Zhang, J., Liang, H., Li, N., Zhu, X., Ding, L., and Huang, B. (2022). Vaccination with Omicron inactivated vaccine in pre-vaccinated mice protects against SARS-CoV-2 prototype and Omicron variants. Vaccines, 10.","DOI":"10.3390\/vaccines10071149"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1080\/14760584.2021.1987223","article-title":"DNA vaccines for SARS-CoV-2: Toward third-generation vaccination era","volume":"20","author":"Chavda","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1016\/j.vaccine.2021.05.098","article-title":"Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models","volume":"39","author":"Dey","year":"2021","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Momin, T., Kansagra, K., Patel, H., Sharma, S., Sharma, B., Patel, J., Mittal, R., Sanmukhani, J., Maithal, K., and Dey, A. (2021). Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India. eClinicalMedicine, 38.","DOI":"10.1016\/j.eclinm.2021.101020"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): The interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Appelberg, S., Ahl\u00e9n, G., Yan, J., Nikouyan, N., Weber, S., Larsson, O., H\u00f6glund, U., Aleman, S., Weber, F., and Perlhamre, E. (2022). A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells. EMBO Mol. Med., 14.","DOI":"10.15252\/emmm.202215821"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.vaccine.2022.12.067","article-title":"Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice","volume":"41","author":"Jang","year":"2023","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Tzeng, T.T., Chai, K.M., Shen, K.Y., Yu, C.Y., Yang, S.J., Huang, W.C., Liao, H.C., Chiu, F.F., Dou, H.Y., and Liao, C.L. (2022). A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection. NPJ Vaccines, 7.","DOI":"10.1038\/s41541-022-00482-0"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Mucker, E.M., Brocato, R.L., Principe, L.M., Kim, R.K., Zeng, X., Smith, J.M., Kwilas, S.A., Kim, S., Horton, H., and Caproni, L. (2022). SARS-CoV-2 doggybone DNA vaccine produces cross-variant neutralizing antibodies and is protective in a COVID-19 animal model. Vaccines, 10.","DOI":"10.3390\/vaccines10071104"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zhang, Z., He, Q., Zhao, W., Li, Y., Yang, J., Hu, Z., Chen, X., Peng, H., Fu, Y.X., and Chen, L. (2022). A heterologous V-01 or variant-matched bivalent V-01D-351 booster following primary series of inactivated vaccine enhances the neutralizing capacity against SARS-CoV-2 Delta and Omicron strains. J. Clin. Med., 11.","DOI":"10.3390\/jcm11144164"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-022-00612-2","article-title":"A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs","volume":"32","author":"Liu","year":"2022","journal-title":"Cell Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41422-022-00631-z","article-title":"A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant","volume":"32","author":"Liu","year":"2022","journal-title":"Cell Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Heide, J., Schulte, S., Kohsar, M., Brehm, T.T., Herrmann, M., Karsten, H., Marget, M., Peine, S., Johansson, A.M., and Sette, A. (2021). Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009842"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lim, H.X., Masomian, M., Khalid, K., Kumar, A.U., MacAry, P.A., and Poh, C.L. (2022). Identification of B-cell epitopes for eliciting neutralizing antibodies against the SARS-CoV-2 spike protein through bioinformatics and monoclonal antibody targeting. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084341"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Boni, C., Cavazzini, D., Bolchi, A., Rossi, M., Vecchi, A., Tiezzi, C., Barili, V., Fisicaro, P., Ferrari, C., and Ottonello, S. (2021). Degenerate CD8 epitopes mapping to structurally constrained regions of the spike protein: A T cell-based way-out from the SARS-CoV-2 variants storm. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.730051"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41590-022-01351-7","article-title":"Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4+ T cell recognition","volume":"23","author":"Tye","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Kingstad-Bakke, B., Lee, W., Chandrasekar, S.S., Gasper, D.J., Salas-Quinchucua, C., Cleven, T., Sullivan, J.A., Talaat, A., Osorio, J.E., and Suresh, M. (2022). Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Proc. Natl. Acad. Sci. USA, 119.","DOI":"10.1073\/pnas.2118312119"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41586-021-04232-5","article-title":"A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity","volume":"601","author":"Heitmann","year":"2022","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Lee, Y.-S., Hong, S.-H., Park, H.-J., Lee, H.-Y., Hwang, J.-Y., Kim, S.Y., Park, J.W., Choi, K.-S., Seong, J.K., and Park, S.-I. (2021). Peptides derived from S and N proteins of severe acute respiratory syndrome coronavirus 2 induce T cell responses: A proof of concept for T cell vaccines. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.732450"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Rosendahl Huber, S., van Beek, J., de Jonge, J., Luytjes, W., and van Baarle, D. (2014). T cell responses to viral infections-opportunities for peptide vaccination. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00171"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1080\/22221751.2022.2140608","article-title":"A novel RBD-protein\/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Wang, C.Y., Hwang, K.P., Kuo, H.K., Peng, W.J., Shen, Y.H., Kuo, B.S., Huang, J.H., Liu, H., Ho, Y.H., and Lin, F. (2022). A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. J. Clin. Investig., 132.","DOI":"10.1172\/JCI157707"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/infdis\/jiac241","article-title":"High neutralizing antibody levels against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 after UB-612 vaccine booster","volume":"226","author":"Guirakhoo","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_59","unstructured":"(2023, January 19). Vaxxinity\u2019s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies against Omicron and Other Variants of Concern. 11 February 2022. Available online: https:\/\/www.biospace.com\/article\/releases\/vaxxinity-s-covid-19-vaccine-candidate-ub-612-produces-high-levels-of-neutralizing-antibodies-against-omicron-and-other-variants-of-concern\/."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"283","DOI":"10.15789\/2220-7619-ASB-1699","article-title":"A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the \u201cEpiVacCorona\u201d Vaccine for the prevention of COVID-19, in volunteers aged 18\u201360 years (phase I\u2013II)","volume":"11","author":"Ryzhikov","year":"2021","journal-title":"Russ. J. Infect. Immun."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Matveeva, O., and Ershov, A. (2022). Retrospective cohort study of the effectiveness of the Sputnik V and EpiVacCorona vaccines against the SARS-CoV-2 Delta variant in Moscow (June\u2013July 2021). Vaccines, 10.","DOI":"10.21203\/rs.3.rs-1700347\/v1"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: Preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.chom.2021.08.002","article-title":"An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates","volume":"29","author":"Zabaleta","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Tscherne, A., Schwarz, J.H., Rohde, C., Kupke, A., Kalodimou, G., Limpinsel, L., Okba, N.M.A., Bo\u0161njak, B., Sandrock, I., and Odak, I. (2021). Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. Proc. Natl. Acad. Sci. USA, 118.","DOI":"10.1073\/pnas.2026207118"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1126\/science.1155761","article-title":"Virus attenuation by genome-scale changes in codon pair bias","volume":"320","author":"Coleman","year":"2008","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Wang, Y., Yang, C., Song, Y., Coleman, J.R., Stawowczyk, M., Tafrova, J., Tasker, S., Boltz, D., Baker, R., and Garcia, L. (2021). Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proc. Natl. Acad. Sci. USA, 118.","DOI":"10.1073\/pnas.2102775118"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Trimpert, J., Dietert, K., Firsching, T.C., Ebert, N., Thi Nhu Thao, T., Vladimirova, D., Kaufer, S., Labroussaa, F., Abdelgawad, A., and Conradie, A. (2021). Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. Cell Rep., 36.","DOI":"10.2139\/ssrn.3783405"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nbt.1635","article-title":"Rationalizing the development of live attenuated virus vaccines","volume":"28","author":"Lauring","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Trimpert, J., Adler, J.M., Eschke, K., Abdelgawad, A., Firsching, T.C., Ebert, N., Thao, T.T.N., Gruber, A.D., Thiel, V., and Osterrieder, N. (2021). Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta). Sci. Adv., 7.","DOI":"10.1126\/sciadv.abk0172"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Kushnir, A., Mueller, S., Tasker, S., and Robert Coleman, J. (2021). 577. COVI-VAC\u2122, a live attenuated COVID-19 vaccine, provides single dose protection against heterologous challenge with SARS-CoV-2 Beta (B.1.351) in the Syrian Golden hamster model. Open Forum. Infect. Dis., 8.","DOI":"10.1093\/ofid\/ofab466.775"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/01410768211053006","article-title":"The costs of coronavirus vaccines and their pricing","volume":"114","author":"Light","year":"2021","journal-title":"J. R. Soc. Med."},{"key":"ref_74","unstructured":"Sheridan, C. (2023, February 03). First COVID-19 DNA Vaccine Approved, Others in Hot Pursuit. 16 November 2021. Available online: https:\/\/www.nature.com\/articles\/d41587-021-00023-5."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/fvl-2021-0170","article-title":"A brief review on DNA vaccines in the era of COVID-19","volume":"17","author":"Shafaati","year":"2022","journal-title":"Future Virol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Hobernik, D., and Bros, M. (2018). DNA Vaccines-How Far From Clinical Use?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113605"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/infdis\/jiac016","article-title":"SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a Phase 1 open-label trial","volume":"225","author":"Kraynyak","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40124-022-00278-9","article-title":"Vaccine hesitancy: Obstacles and challenges","volume":"10","author":"Galagali","year":"2022","journal-title":"Curr. Pediatr. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Abdul Karim, M., Reagu, S.M., Ouanes, S., Waheed Khan, A., Smidi, W.S., Al-Baz, N., and Alabdulla, M. (2022). Prevalence and correlates of COVID-19 vaccine hesitancy among the elderly in Qatar: A cross-sectional study. Medicine (Baltimore), 101.","DOI":"10.1097\/MD.0000000000029741"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M21-4502","article-title":"Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021","volume":"175","author":"See","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1080\/21645515.2021.1911204","article-title":"COVID-19 vaccine platforms: Delivering on a promise?","volume":"17","author":"Verdecia","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Liu, M.A. (2019). A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines, 7.","DOI":"10.3390\/vaccines7020037"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Di Natale, C., La Manna, S., De Benedictis, I., Brandi, P., and Marasco, D. (2020). Perspectives in peptide-based vaccination strategies for syndrome coronavirus 2 pandemic. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.578382"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Khairkhah, N., Bolhassani, A., Agi, E., Namvar, A., and Nikyar, A. (2022). Immunological investigation of a multiepitope peptide vaccine candidate based on main proteins of SARS-CoV-2 pathogen. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0268251"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(21)02844-0","article-title":"Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum","volume":"399","author":"Dejnirattisai","year":"2022","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41564-021-01053-0","article-title":"Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario","volume":"7","author":"Nasreen","year":"2022","journal-title":"Nat. Microbiol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Baraniuk, C. (2021). Covid-19: How effective are vaccines against the delta variant?. BMJ, 374.","DOI":"10.1136\/bmj.n1960"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for covid-19","volume":"384","author":"Suthar","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.it.2022.01.009","article-title":"Developing pan-\u03b2-coronavirus vaccines against emerging SARS-CoV-2 variants of concern","volume":"43","author":"Su","year":"2022","journal-title":"Trends Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41590-021-01028-7","article-title":"Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection","volume":"22","author":"Smith","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Wang, Z., Lorenzi, J.C.C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., Hoffmann, H.H., Oliveira, T.Y., and Oren, D.A. (2021). Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med., 13.","DOI":"10.1126\/scitranslmed.abf1555"},{"key":"ref_93","unstructured":"Staff, T. (The Times of Israel, 2022). Omicron Wave Could Mark End of Pandemic, Israeli COVID Expert Says, The Times of Israel."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMp2113403","article-title":"The future of SARS-CoV-2 vaccination-lessons from Influenza","volume":"385","author":"Monto","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Lippi, G., Henry, B.M., and Plebani, M. (2021). Anti-SARS-CoV-2 antibodies testing in recipients of COVID-19 vaccination: Why, when, and how?. Diagnostics, 11.","DOI":"10.3390\/diagnostics11060941"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Ward, H., Whitaker, M., Flower, B., Tang, S.N., Atchison, C., Darzi, A., Donnelly, C.A., Cann, A., Diggle, P.J., and Ashby, D. (2022). Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat. Commun., 13.","DOI":"10.1038\/s41467-022-28527-x"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Bagwe, P.V., Bagwe, P.V., Ponugoti, S.S., and Joshi, S.V. (2022). Peptide-based vaccines and therapeutics for COVID-19. Int. J. Pept. Res. Ther., 28.","DOI":"10.1007\/s10989-022-10397-y"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/3\/624\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:41:57Z","timestamp":1760121717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/3\/624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":97,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["v15030624"],"URL":"https:\/\/doi.org\/10.3390\/v15030624","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]}}}